Sign in

CIK 0001725160

  • Non-accelerated filer
  • Smaller reporting company

Zentalis Pharmaceuticals, Inc.

Sign in to watch
Ticker
ZNTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
823607803
Phone
+1 858-263-4333
Business address
10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
Former names
Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Grant or award Director acquired 57,603 shares (grant or award)
  4. 4 Grant or award Director acquired 57,603 shares (grant or award)
  5. 4 Grant or award Director acquired 57,603 shares (grant or award)
  6. 4 Grant or award Director acquired 57,603 shares (grant or award)
  7. 4 Grant or award Director acquired 57,603 shares (grant or award)
  8. 4 Open-market buy Director bought 21,000 shares at $1.40 ($29,373)
  9. 4 Open-market buy Chief Medical Officer bought 20,000 shares at $2.28 ($45,656)
  10. 4 Open-market sale PAO and Interim PFO sold 2,615 shares at $1.71 ($4,476)
  11. 4 Open-market sale Chief Scientific Officer sold 14,368 shares at $1.71 ($24,591)
  12. 4 Open-market sale Chief Legal Officer sold 13,230 shares at $1.71 ($22,643)
  13. 4 Grant or award Chief Medical Officer acquired 16,629 shares (grant or award)
  14. 4 Grant or award CEO & President acquired 59,388 shares (grant or award)
  15. 4 Open-market buy Director bought 60,000 shares at $1.72 ($103,446)
  16. 4 Open-market buy Director bought 14,200 shares at $1.76 ($24,966)
  17. 4 Open-market buy CEO & President bought 28,500 shares at $1.73 ($49,345)
  18. 4 Open-market sale Chief Scientific Officer sold 4,411 shares at $3.12 ($13,762)
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 2 of 13 · 252 filings